舒巴坦

shū bā tǎn
  • Sulbactam
舒巴坦舒巴坦
  1. 目的:研究阿莫西林(AMC)/舒巴坦(SBT)不同配比(2:1和4:1)对临床分离致病菌的体外抗菌活性。

    Objective : To evaluate the antibacterial activities in vitro of amoxicillin / sulbactam ( 2:1 and 4:1 ) .

  2. 方法:选择4℃、25℃、37℃,在3h内观察配伍液外观、pH值变化,并用RP-HPLC法测定阿莫西林与舒巴坦的含量。

    Method The external appearance and PH values of the mixed solution were observed , and the contents of Amoxicillin and Sulbactam were determined by RP-HPLC method at 4 ℃、 25 ℃、 37 ℃ for 3 hours .

  3. 对氨苄西林-舒巴坦也有一定的耐药,TEM基因阳性志贺菌、TEM基因阴性志贺菌的耐药率分别为41.2%、20.6%。

    About 41.2 % of TEM-gene positive S.flexneri and 20.6 % of TEM-gene negative S.flexneri were resistant to ampicillin-sulbactam .

  4. 结论10mg/0.1mL的头孢哌酮/舒巴坦玻璃体腔注射是一个安全剂量。

    Conclusion 10 mg of Celoperazone / Sulbaclam is a safe dosage for rabbit intravitreal injection .

  5. 舒巴坦可以使头孢他啶对大肠杆菌、阴沟肠杆菌、弗劳地枸橼酸杆菌、不动杆菌属、铜绿假单胞菌的MIC90降低4倍;

    Cloacae , C. freundii , Acinetobacter spp. , P.aeruginosa 4 folds and reduced the MIC90 of cefotaxime against E.

  6. 目的:测定头孢哌酮和哌拉西林与克拉维酸、舒巴坦、三唑巴坦3种β内酰胺酶抑制剂的复合制剂的最小抑菌浓度(MIC)、杀菌曲线。

    Objective : To measure the minimal inhibitory concentration ( MIC ), time-kill curve of the composite preparation of β - lactams and β - lactamase inhibitors against β - lactamase-producing Gram-negative bacteria in vitro .

  7. 氨苄西林与舒巴坦以2∶1、4∶1配比联用时,其对分离产酶菌的MIC值分别降低10~40倍、10~20倍。

    MICs of ampicillin against lactamase-producing isolates decreased by 10-40 and 10-20 times , respectively , when it was conbined with sulbactam at ratio of 1 2 and 1 4 . All clinical isolates were susceptible to third-generation cephalosporins .

  8. 产ESBLs株对亚胺培南均呈敏感,对头孢西丁、头孢哌酮-舒巴坦及哌拉西林-三唑巴坦耐药率较低,对其他抗菌药物的耐药率均较不产ESBLs株高。

    All ESBLs producing strains in our study were susceptible to imipenem , and relatively susceptible to cefoxitin , cefoperazone-sulbactam and piperacillin-tazobactam . ESBLs-producers had much higher resistance rates to other antimicrobial agents compared with ESBLs non-producing strains .

  9. 目的研究头孢哌酮(CPZ)及不同配比头孢哌酮/舒巴坦(CPZ/SBT)对临床分离致病菌的体外抗菌活性,为临床提供用药依据。

    Objective To study the antibacterial activity in vitro of cefoperazone ( CPZ ) and different ratio of cefoperazone / sulbactam ( CPZ / SBT ) and to supply the clinical doctors with useful information .

  10. 本文进行了8名健康男性志愿者交叉口服两种舒他西林片剂的生物等效性试验,给药剂量为750mg,建立了HPLC法测定血清中氨苄西林(AMP)、舒巴坦(SBT)的药物浓度。

    Healthy male volunteers were enrolled in a two period cross-over bioequivalent study of sultamicillin tablet , HPLC method was established and used to assay the concentration of the active metabolites of sultamicillin-ampicillin and sulbactam in human serum after oral administration of 750 mg sultamicillin tablets .

  11. 比较头孢哌酮/舒巴坦(CPZ/SB)、亚胺培南/西司他丁(IPM/CS)与头孢他啶(CAZ)治疗老年人肺部感染的疗效及其安全性。

    To evaluate the efficacy and safety of cefperazone / sulbactam ( CPZ / SB ) , imipenem / cilastatin ( IPM / CS ) versus ceftazidime ( CAZ ) in the treatment of lower respiratory tract infections in the elderly .

  12. 舒巴坦/头孢哌酮与头孢噻肟随机对照多中心临床研究

    Multicenter randomized controlled clinical trial on sulbactam / cefoperazone versus cefotaxime

  13. 头孢哌酮-舒巴坦(商品名舒普深)与头孢曲松治疗新生儿肺炎对照分析

    Comparing sulbactam - cefoperazone and cefotaxime in treatment pneumonia of infant

  14. 舒巴坦/头孢哌酮治疗老年人下呼吸道感染疗效的临床评价

    Treatment of lower respiratory infections with sulbactam / cefoperazone of elderly

  15. 舒巴坦与β-内酰胺抗生素联用的体外抗菌活性研究

    In vitro antibacterial activities of sulbactam plus β - lactam antibiotics

  16. 头孢哌酮/舒巴坦在开胸术后感染治疗中的评价

    Evaluation of Cefoperazone / Sulbactam in the Treatment of Chest Postoperative Infection

  17. 舒巴坦与米诺环素对多药耐药鲍氏不动杆菌体外联合药敏研究

    In-vitro Activity of Sulbactam in Combination with Minocycline Against Multidrug-resistant Acinetobacter baumannii

  18. 舒巴坦的工艺优化研究

    Research of the Optimizing Process of Sulbactam

  19. 舒巴坦匹酯原料残留溶剂的评价

    Evaluation of Residual Solvent in Sulbactam Pivoxil

  20. 氨苄西林/舒巴坦的临床评价

    Clinical evaluation of ampicillin / sulbactam

  21. 结论头孢哌酮/舒巴坦是一种抗菌谱广、疗效显著、副作用少的抗菌药物,特别适用于重症下呼吸道医院感染的疾病治疗。

    CONCLUSIONS Sulperazone is effective and safe in the treatment of severe nosocomial lower respiratory infection .

  22. 头孢哌酮/舒巴坦体内外抗菌活性及其与细菌β-内酰胺酶的关系

    In vitro and in vivo antibacterial activities of cefoperazone / sulbactam and their relationships with β lactamase

  23. 方法:用平皿二倍稀释法测定了舒巴坦与头孢他啶、头孢噻肟、头孢呋辛1:1联合的体外抗菌作用。

    METHODS : The in vitro combination antibacterial activities were studied by using two-fold plate dilution methods .

  24. 乳酸左氧氟沙星与头孢哌酮/舒巴坦对照治疗老年人呼吸道感染的临床研究

    Clinical evaluation of levofloxacin lactate and cefoperazone / sulbactam in the treatment of respiratory tract infections in elderly patients

  25. 目的研究(1∶1)头孢哌酮(第3代头孢类抗生素)/舒巴坦(β内酰胺酶抑制剂)在成年与老年的药代动力学。

    Objective To study the pharmacokinetics of cefoperazone and sulbactam ( 1 ∶ 1 ) in healthy adult and old people .

  26. 方法:应用计算机辅助褶合曲线分析法,结合计算机信息处理技术,同时测定头孢哌酮和舒巴坦的含量。

    Methods : The computer aided convolution curve method has been applied to determine the content of cefoperazone and sulbactam simultaneously .

  27. 目的研究比较静脉滴注哌拉西林/舒巴坦(4∶1)复方制剂在健康志愿者中的药动学。

    Objective To study the pharmacokinetics of a single dose of piperacillin / sulbactam ( 4 ∶ 1 ) injection in healthy volunteers .

  28. 对β-内酰胺类抗生素复合剂哌拉西林胞唑巴坦(P/T)、氨苄西林/舒巴坦(A/S)敏感率分别为75.8%和3.5%;

    The sensitive rate of - lactam comparator P / T , A / S was 75.8 % , 3.5 % , respectively .

  29. 结论:哌拉西林/舒巴坦(1:1、2:1、4:1)是一个有效的β-内酰胺酶抑制剂联合制剂,三种配比的哌拉西林/舒巴坦体外抗菌活性相似,有进一步研究开发价值。

    CONCLUSION : Piperacillin / sulbactam ( 1:1,2:1 , 4:1 ) is a effective antibiotic containing β - lactamases inhibitor and valuable to be investigated .

  30. 将米诺环素和头孢哌酮/舒巴坦(1:1)的药物浓度依次倍比稀释,设置11个稀释浓度。

    The effects of minocycline and cefoperazone / sulbactam ( 1:1 ) drug concentrations in turn times than dilution , set a dilution 11 concentration .